UPClytics
View all cases

UPC APP 10151/2025

Feb 27, 2025·EP2501384 · METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY

Case details
Status
Case Closed
Action
Generic
Category
File-access requests (R. 262.1(b))
Parties
Claimants
Representatives
  • Phillip Rektorschek
Respondents
Representatives
Division
Milan CD
Technology
  • Chemistry
    Organic fine chemistry · Pharmaceuticals
Language
English
First decided
Apr 10, 2025
EPO Opposition
  • Fresenius Kabi Deutschland GmbHAdmissible2016-11-14
  • Hamm&Wittkopp Patentanwälte PartmbBAdmissible2016-11-17
  • Teva Pharmaceutical Industries LtdAdmissible2016-11-17
  • Intas Pharmaceuticals Ltd.Admissible2016-11-17
  • Generics (U.K.) LimitedAdmissible2016-11-17
  • TEVA PHARMACEUTICAL INDUSTRIES, LTD.Admissible2016-11-17
How this compares
How long the court takes to reach a first decision.
Median days to first decision
All UPC124
Milan CDLocked
Judge Andrea PostiglioneLocked
Judge Marije KnijffLocked
Judge Oliver WernerLocked

At the UPC: ALIUD PHARMA GmbH (1 case)·Accord Group (8 cases)

1 other defendants litigating the same or a related patent

UPC APP 9038/2025

Start a free trial to see how each one ended.

More cases: Milan CD·2025

Decisions
  • 2025-04-10
    Application RoP262.1 (b)Public

    Summary: The Milan Central Division granted ALIUD PHARMA's application for access to pleadings filed in closed proceedings between Accord Healthcare and Novartis (EP 2 501 384) under R. 262.1(b) RoP, after Novartis withdrew its objection following settlement of the main proceedings.

    Show the legal issues (3)
    • R. 262.1(b) public access to file
    • Access to pleadings after case closure
    • Redaction of personal data
Document titleDatePublic
Headnote-and-Keywords2025-04-10Not public
Outcome of the Order2025-04-10Not public
ORDER2025-04-10Public
Template-Order2025-04-10Not public
Comments2025-04-03Not public
Comments2025-04-03Not public
25-03-27_-_Statement_re_request_pursuant_R._262_(1)b_RoP2025-03-27Not public
Annex FS202025-03-27Not public
Annex FS202025-03-27Not public
ORDER 12 MARCH 20252025-03-12Not public